Table 5.
Summary of patients’ characteristics and their frequency among reported cases
| Onset up to 1 week after COVID-19 | Onset at least 1 week after COVID-19 | |
| Adult patients | 4 | 24 |
| Juvenile patients | 3 | 2 |
| Male | 6 | 13 |
| Female | 1 | 13 |
| Peripheral joint involvement | 7 | 24 |
|
2 | 8 |
|
2 | 3 |
|
3 | 8 |
|
0 | 2 |
|
0 | 3 |
| Axial involvement | 0 | 4 |
| Positive ANAs | 0 | 1 |
| Positive RF | 0 | 1 |
| Positive ACPA | 1 | 0 |
| Positive HLA B27+ | 1 | 3 |
| No treatment | 1 | 1 |
| NSAIDs/Analgesics | 4 | 19 |
| Glucocorticoids | 3 | 13 |
| csDMARDs | 0 | 0 |
| Remission | 6 | 20 |
| Minor residual symptoms | 1 | 6 |
ACPA, anticitrullinated protein antibodies; ANA, antinuclear antibodies; csDMARD, conventional synthetic disease-modifying antirheumatic drug; HLA, human leucocyte antigen; NSAID, non-steroid anti-inflammatory drug; RF, rheumatoid factor.